Clash of the titans: axi-cel versus tisa-cel for advanced-stage dlbcl

Clash of the titans: axi-cel versus tisa-cel for advanced-stage dlbcl

Play all audios:

Loading...

CAR T cell therapy has altered the natural history of relapsed and/or refractory diffuse large B cell lymphoma (DLBCL). However, the availability of multiple products has created provider uncertainty regarding treatment selection and the need to balance toxicity and efficacy. In a retrospective analysis, the authors suggest that axicabtagene ciloleucel might be superior to tisagenlecleucel. However, several questions remain unresolved. Access through your institution Buy or subscribe This is a preview of subscription content, access via your institution ACCESS OPTIONS Access through your institution Access Nature and 54 other Nature Portfolio journals Get Nature+, our best-value online-access subscription $29.99 / 30 days cancel any time Learn more Subscribe to this journal Receive 12 print issues and online access $209.00 per year only $17.42 per issue Learn more Buy this article * Purchase on SpringerLink * Instant access to full article PDF Buy now Prices may be subject to local taxes which are calculated during checkout ADDITIONAL ACCESS OPTIONS: * Log in * Learn about institutional subscriptions * Read our FAQs * Contact customer support REFERENCES * Hu, Z. H., Peter Gale, R. & Zhang, M. J. Direct adjusted survival and cumulative incidence curves for observational studies. _Bone Marrow Transplant._ 55, 538–543 (2020). Article  Google Scholar  * Khera, N. et al. Comparison of characteristics and outcomes of trial participants and nonparticipants: example of blood and marrow transplant clinical trials network 0201 trial. _Biol. Blood Marrow Transplant._ 21, 1815–1822 (2015). Article  Google Scholar  * Bachy, E. et al. A real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B cell lymphoma. _Nat. Med._ 28, 2145–2154 (2022). Article  CAS  Google Scholar  * Brookhart, M. A. et al. Variable selection for propensity score models. _Am. J. Epidemiol._ 163, 1149–1156 (2006). Article  Google Scholar  * Bethge, W. A. et al. GLA/DRST real-world outcome analysis of CAR T-cell therapies for large B-cell lymphoma in Germany. _Blood_ 140, 349–358 (2022). CAS  Google Scholar  * Gauthier, J. et al. Impact of CD19 CAR T-cell product type on outcomes in relapsed or refractory aggressive B-NHL. _Blood_ 139, 3722–3731 (2022). Article  CAS  Google Scholar  * Riedell, P. A. et al. Patterns of use, outcomes, and resource utilization among recipients of commercial axicabtagene ciloleucel and tisagenlecleucel for relapsed/refractory aggressive B cell lymphomas. _Transplant Cell Ther._ 28, 669–676 (2022). Article  Google Scholar  * Oluwole, O. O. et al. Prophylactic corticosteroid use in patients receiving axicabtagene ciloleucel for large B-cell lymphoma. _Br. J. Haematol._ 194, 690–700 (2021). Article  CAS  Google Scholar  * NICE. Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people aged up to 25 years. _nice.org.uk_, https://www.nice.org.uk/guidance/ta554 (21 December 2022). * ICER. Leukemia and Lymphoma. _icer.org_ https://icer.org/assessment/leukemia-and-lymphoma-2018 (March 2018). Download references AUTHOR INFORMATION AUTHORS AND AFFILIATIONS * Center for Hematologic Malignancies, Knight Cancer Institute, Oregon Health and Science University, Portland, OR, USA Richard T. Maziarz * Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA, USA Jordan Gauthier * Department of Medicine, University of Washington, Seattle, WA, USA Jordan Gauthier Authors * Richard T. Maziarz View author publications You can also search for this author inPubMed Google Scholar * Jordan Gauthier View author publications You can also search for this author inPubMed Google Scholar CORRESPONDING AUTHOR Correspondence to Richard T. Maziarz. ETHICS DECLARATIONS COMPETING INTERESTS R.T.M. has acted as a consultant and/or adviser of Artiva Therapeutics, Bristol-Myers Squibb/Celgene, CRISPR Therapeutics, Incyte, Kite and Novartis and has received research funding from BMS and Novartis. J.G. has acted as a consultant and/or adviser of Janssen, Kite Pharma, Legend Biotech and MorphoSys and has received research funding from Angiocrine Bioscience, Celgene (a BMS company), Juno Therapeutics (a BMS company) and Sobi. RIGHTS AND PERMISSIONS Reprints and permissions ABOUT THIS ARTICLE CITE THIS ARTICLE Maziarz, R.T., Gauthier, J. Clash of the titans: axi-cel versus tisa-cel for advanced-stage DLBCL. _Nat Rev Clin Oncol_ 20, 5–6 (2023). https://doi.org/10.1038/s41571-022-00711-4 Download citation * Published: 15 November 2022 * Issue Date: January 2023 * DOI: https://doi.org/10.1038/s41571-022-00711-4 SHARE THIS ARTICLE Anyone you share the following link with will be able to read this content: Get shareable link Sorry, a shareable link is not currently available for this article. Copy to clipboard Provided by the Springer Nature SharedIt content-sharing initiative

CAR T cell therapy has altered the natural history of relapsed and/or refractory diffuse large B cell lymphoma (DLBCL). However, the availability of multiple products has created provider


uncertainty regarding treatment selection and the need to balance toxicity and efficacy. In a retrospective analysis, the authors suggest that axicabtagene ciloleucel might be superior to


tisagenlecleucel. However, several questions remain unresolved. Access through your institution Buy or subscribe This is a preview of subscription content, access via your institution ACCESS


OPTIONS Access through your institution Access Nature and 54 other Nature Portfolio journals Get Nature+, our best-value online-access subscription $29.99 / 30 days cancel any time Learn


more Subscribe to this journal Receive 12 print issues and online access $209.00 per year only $17.42 per issue Learn more Buy this article * Purchase on SpringerLink * Instant access to


full article PDF Buy now Prices may be subject to local taxes which are calculated during checkout ADDITIONAL ACCESS OPTIONS: * Log in * Learn about institutional subscriptions * Read our


FAQs * Contact customer support REFERENCES * Hu, Z. H., Peter Gale, R. & Zhang, M. J. Direct adjusted survival and cumulative incidence curves for observational studies. _Bone Marrow


Transplant._ 55, 538–543 (2020). Article  Google Scholar  * Khera, N. et al. Comparison of characteristics and outcomes of trial participants and nonparticipants: example of blood and marrow


transplant clinical trials network 0201 trial. _Biol. Blood Marrow Transplant._ 21, 1815–1822 (2015). Article  Google Scholar  * Bachy, E. et al. A real-world comparison of tisagenlecleucel


and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B cell lymphoma. _Nat. Med._ 28, 2145–2154 (2022). Article  CAS  Google Scholar  * Brookhart, M. A. et al.


Variable selection for propensity score models. _Am. J. Epidemiol._ 163, 1149–1156 (2006). Article  Google Scholar  * Bethge, W. A. et al. GLA/DRST real-world outcome analysis of CAR T-cell


therapies for large B-cell lymphoma in Germany. _Blood_ 140, 349–358 (2022). CAS  Google Scholar  * Gauthier, J. et al. Impact of CD19 CAR T-cell product type on outcomes in relapsed or


refractory aggressive B-NHL. _Blood_ 139, 3722–3731 (2022). Article  CAS  Google Scholar  * Riedell, P. A. et al. Patterns of use, outcomes, and resource utilization among recipients of


commercial axicabtagene ciloleucel and tisagenlecleucel for relapsed/refractory aggressive B cell lymphomas. _Transplant Cell Ther._ 28, 669–676 (2022). Article  Google Scholar  * Oluwole,


O. O. et al. Prophylactic corticosteroid use in patients receiving axicabtagene ciloleucel for large B-cell lymphoma. _Br. J. Haematol._ 194, 690–700 (2021). Article  CAS  Google Scholar  *


NICE. Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people aged up to 25 years. _nice.org.uk_, https://www.nice.org.uk/guidance/ta554 (21


December 2022). * ICER. Leukemia and Lymphoma. _icer.org_ https://icer.org/assessment/leukemia-and-lymphoma-2018 (March 2018). Download references AUTHOR INFORMATION AUTHORS AND AFFILIATIONS


* Center for Hematologic Malignancies, Knight Cancer Institute, Oregon Health and Science University, Portland, OR, USA Richard T. Maziarz * Clinical Research Division, Fred Hutchinson


Cancer Center, Seattle, WA, USA Jordan Gauthier * Department of Medicine, University of Washington, Seattle, WA, USA Jordan Gauthier Authors * Richard T. Maziarz View author publications You


can also search for this author inPubMed Google Scholar * Jordan Gauthier View author publications You can also search for this author inPubMed Google Scholar CORRESPONDING AUTHOR


Correspondence to Richard T. Maziarz. ETHICS DECLARATIONS COMPETING INTERESTS R.T.M. has acted as a consultant and/or adviser of Artiva Therapeutics, Bristol-Myers Squibb/Celgene, CRISPR


Therapeutics, Incyte, Kite and Novartis and has received research funding from BMS and Novartis. J.G. has acted as a consultant and/or adviser of Janssen, Kite Pharma, Legend Biotech and


MorphoSys and has received research funding from Angiocrine Bioscience, Celgene (a BMS company), Juno Therapeutics (a BMS company) and Sobi. RIGHTS AND PERMISSIONS Reprints and permissions


ABOUT THIS ARTICLE CITE THIS ARTICLE Maziarz, R.T., Gauthier, J. Clash of the titans: axi-cel versus tisa-cel for advanced-stage DLBCL. _Nat Rev Clin Oncol_ 20, 5–6 (2023).


https://doi.org/10.1038/s41571-022-00711-4 Download citation * Published: 15 November 2022 * Issue Date: January 2023 * DOI: https://doi.org/10.1038/s41571-022-00711-4 SHARE THIS ARTICLE


Anyone you share the following link with will be able to read this content: Get shareable link Sorry, a shareable link is not currently available for this article. Copy to clipboard Provided


by the Springer Nature SharedIt content-sharing initiative